Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold

Astellas Pharma saw its FY2020 group sales fall 3.9% year on year as its Japan business floundered due to the discontinuation of collaboration deals, which could not be countered by double-digit growth delivered by its flagship cancer drug Xtandi (enzalutamide)...read more